Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.


Journal

Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 14 8 2019
medline: 28 3 2020
entrez: 14 8 2019
Statut: ppublish

Résumé

Endothelial cells (EC) are targets in gene therapy and regenerative medicine, but they are inefficiently transduced with adeno-associated virus (AAV) vectors of various serotypes. To identify barriers hampering efficient transduction and to develop an optimized AAV variant for EC transduction, we screened an AAV serotype 2-based peptide display library on primary human macrovascular EC. Using a new high-throughput selection and monitoring protocol, we identified a capsid variant, AAV-V

Identifiants

pubmed: 31407607
doi: 10.1089/hum.2019.027
doi:

Substances chimiques

Peptide Library 0
Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1284-1296

Auteurs

L Zhang (L)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Pathology, University Hospital of Cologne, Cologne, Germany.

A Rossi (A)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
International Center for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, Lyon, France.

L Lange (L)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.

N Meumann (N)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

U Koitzsch (U)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Pathology, University Hospital of Cologne, Cologne, Germany.

K Christie (K)

Biomedical Sciences Research Institute, Ulster University, Ulster, Northern Ireland.

M A Nesbit (MA)

Biomedical Sciences Research Institute, Ulster University, Ulster, Northern Ireland.

C B T Moore (CBT)

Biomedical Sciences Research Institute, Ulster University, Ulster, Northern Ireland.
Avellino Labs USA, Menlo Park, California.

U T Hacker (UT)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
1st Medical Department, University Cancer Center Leipzig, University Leipzig Medical Center, Leipzig, Germany.

M Morgan (M)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.

D Hoffmann (D)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.

J Zengel (J)

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.

J E Carette (JE)

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.

A Schambach (A)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

A Salvetti (A)

International Center for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, Lyon, France.

M Odenthal (M)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Pathology, University Hospital of Cologne, Cologne, Germany.

H Büning (H)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
German Center for Infection Research (DZIF), Partner Sites Bonn-Cologne and Hannover-Braunschweig, Braunschweig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH